
A Nurse Led Fibroscan® Outreach Clinic Encourages Socially Deprived Heavy Drinkers to Engage with Liver Services

Background

- •CLD 3rd largest cause of death in UK
- Most liver disease undiagnosed and untreated
- Alcohol plays a major role in development of cirrhosis
- Health inequality gap increasing



Research Context

- Collaborative service
- Drug and alcohol support
- Housing/Social support
- Visiting agencies
- Footfall 60-70 daily



Aims and Objectives

- Record uptake
- Determine prevalence
- Report engagement



Method


- Numbered information packs
- ≤7kPa no referral
- >7kPa referral to nurse led liver clinic
- Monitor attendance via Trak for 6 months



Fig. 6. Clinical significance of liver stiffness cut-offs in chronic liver diseases. When liver stiffness values range between 2.5 and 7 kPa, mild or absent fibrosis is likely, whereas when liver stiffness values are above 12.5 kPa, cirrhosis is likely.


Uptake of Fibroscan n=118

■ Participants (n=79) ■ Non participants (n=39)



Demographics (n=79)

- Mean age= 46 years
- 63% male
- 37% female
- 87% linked with alcohol services
- 70% previous attempts at detox
- 5% currently abstinent
- 75% daily drinkers, 22% binge, 4% intermittent



Demographics (n=79)


- Mean length of drinking = 15 years
- 70% drank > 100units weekly
- 86% no symptoms of concern
- Mean BMI= 26.5kg/m²
- Risk of BBVs= 72%



Fibroscan results n=76


- ≤7kPa (n=56)
- \blacksquare \geq 8kPa <12.5kPa (n=7)

- >7kPa <8kPa (n=8)
- ≥ 12.5 kPa (n=5)



Diagnostic outcomes n=76

- Cirrhotic (n=6)
- Fibrotic (n=4)
- Undiagnosed in nurse follow up (n=1)
- Non fibrotic discharged (n=1)
- Seen by nurse but no need for medical referral (n=8)




Engagement

Engagement of those requiring onward referral	Expected number	Number attended	Percentage
Attended nurse appointment at the Hub	20	19	95%
Attended first medical appointment at RIE	12	11	92%
Attended six month follow up	10	9	90%
Attended USS	12	12	100%

Theory informing Discussion

- Self efficacy
- Theory of planned behaviour
- Health belief model
- Multi-component complex intervention
- Normalisation process theory



Conclusion

A nurse led Fibroscan[®] outreach clinic enables:

early identification of liver disease

 encourages socially deprived drinkers to engage with liver services



References

CASTERA L, FORNS X AND ALBERTI A. 2008. *Non-invasive evaluation of liver fibrosis using transient elastography.* Journal of Hepatology. Vol 48(5). Pg. 835-847

SCOTTISH PUBLIC HEALTH OBSERVATORY (ScotPHO)., 2015. *Public Health Information for Scotland* [online]. [Viewed 9 August 2015] Available from:https://scotpho.nhsnss.scot.nhs.uk/scotpho/homeAction.do.

VERRILL C, MARKHAM H, TEMPLETON A, CARR NJ, SHERON N. 2009. *Alcohol-related cirrhosis - early abstinence is a key factor in prognosis*, even in the most severe cases. Addiction 2009;104:768-74.

WATT, G., 2013. What can the NHS do to prevent and reduce health inequalities? *The British Journal of General Practice: The Journal of the Royal College of General Practitioners*. 63, 494-495, doi: 10.3399/bjgp13X671803.

WILLIAMS, R., ASPINAL, R., BELLIS, M., CAMPS-WALSH, G., CRAMP, M., DHAWAN, A., FERGUSON, J., FORTON, D., FOSTER, G., GILMORE, I., HICKMAN, M., HUDSON, M., KELLY, D., LANGFORD, A., LOMBARD, M., LONGWORTH, L., MARTIN, N., MORIARTY, K., NEWSOME, P., O'GRADY, J., PRYKE, R., RUTTER, H., RYDER, S., SHERON, N. and AND SMITH, T., 2014. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *Lancet*. vol. 384, pp. 1953-1997.

SCHWABL, P. (1,2), BOTA, S. (1,2), SAZL, P. (1,2), MANDORFER, M. (1,2), PAYER, B.A. (1,2), FERLITCH, A. (1,2), TRAUNER, M. (1,2), PECK-RADOSAVLJEVIC, M., REIBERGERR, T. (1,2), STIFT, J.(.3.). and WRBA, F.(.3.)., 2015. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. *Liver International.* / 02 / 01 /, vol. 35, no. 2, pp. 381-390









Questions??



Contact details:

kmatthews@qmu.ac.uk or karen.matthews@nhslothian.scot.nhs.uk